ABSTRACT
Carcinoma of the endometrium is the most common invasive gynecologic neoplasm in women in the United States. Over 30,000 new cases will be diagnosed this year. One of the most controversial topics in the field of gynecologic oncology is the postoperative management of patients with edometrial cancer (EC) and uterine sarcoma (US). The majority of patients with EC present with stage I or II disease. The survival of these patients, when treated with surgery only, ranges from 70% to 80%. Identifying the subset of patients at risk for
recurrent disease and the appropriate treatment of these patients often elicits strong opinions from oncologists. Patients with uterine sarcomas often present with advanced pathologically staged disease that puts the patients at high risk for developing distant metastatic disease for which there is no good prophylactic treatment. The Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG) have initiated several clinical trials for patients with EC and US. Unfortunately, many of these clinical trials failed to accrue a sufficient number of patients to permit completion of the study and data analysis.
